Patents by Inventor Neil Josephson

Neil Josephson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF REDUCING SIDE EFFECTS OF ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY
    Publication number: 20240245753
    Abstract: The present disclosure, relates, in general to methods for improving adverse events in subjects having a mature T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.
    Type: Application
    Filed: August 14, 2023
    Publication date: July 25, 2024
    Inventors: Thomas Manley, Neil Josephson
  • Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
    Patent number: 11795229
    Abstract: The present disclosure, relates, in general to methods for improving adverse events in subjects receiving treatment with an anti-CD30 antibody drug conjugate, optionally also receiving accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: October 24, 2023
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Thomas Manley, Neil Josephson
  • METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY
    Publication number: 20230002828
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Application
    Filed: February 25, 2022
    Publication date: January 5, 2023
    Inventors: Haiyan JIANG, Tongyao LIU, Sriram KRISHNAMOORTHY, Neil JOSEPHSON, Glenn PIERCE
  • ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT
    Publication number: 20220298243
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Application
    Filed: April 7, 2022
    Publication date: September 22, 2022
    Applicants: Bristol-Myers Squibb Company, Seattle Genetics, Inc.
    Inventors: Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
  • METHODS OF REDUCING SIDE EFFECTS OF ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY
    Publication number: 20220226439
    Abstract: The present disclosure, relates, in general to methods for improving adverse events in subjects having a mature T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.
    Type: Application
    Filed: November 1, 2018
    Publication date: July 21, 2022
    Inventors: Thomas Manley, Neil Josephson
  • Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
    Patent number: 11299543
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: April 12, 2022
    Assignees: Bristol-Myers Squibb Company, Seattle Genetics. Tnc.
    Inventors: Benedetto Farsaci, Neil Josephson, Anthony Cao, Ryan Heiser
  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
    Patent number: 11286528
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 29, 2022
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • Methods of Reducing Side Effects of Anti-CD30 Antibody Drug Conjugate Therapy
    Publication number: 20210221901
    Abstract: The present disclosure, relates, in general to methods for improving adverse events in subjects receiving treatment with an anti-CD30 antibody drug conjugate, optionally also receiving accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.
    Type: Application
    Filed: October 11, 2018
    Publication date: July 22, 2021
    Inventors: Thomas Manley, Neil Josephson
  • Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
    Publication number: 20200102399
    Abstract: The present disclosure, relates, in general to methods treating peripheral T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy.
    Type: Application
    Filed: October 1, 2019
    Publication date: April 2, 2020
    Inventors: Thomas Manley, Neil Josephson
  • METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY
    Publication number: 20190241960
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Application
    Filed: January 11, 2019
    Publication date: August 8, 2019
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT
    Publication number: 20190218293
    Abstract: The application provides to methods for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising—nivolumab, or pembrolizumab, two PD-1-blocking antibodies that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma in combination with—an anti CD30 antibody, such as brentuximab vedotin.
    Type: Application
    Filed: June 1, 2017
    Publication date: July 18, 2019
    Applicants: Bristol-Myers Squibb Company, Seattle Genetics, Inc.
    Inventors: Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
    Patent number: 10221455
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: March 5, 2019
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY
    Publication number: 20140370035
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Application
    Filed: January 12, 2013
    Publication date: December 18, 2014
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce